OptimizeRx Co. (NASDAQ:OPRX – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $44.71.
Several research firms recently issued reports on OPRX. TheStreet lowered shares of OptimizeRx from a “c-” rating to a “d+” rating in a report on Thursday, September 1st. Piper Sandler cut their price objective on shares of OptimizeRx from $29.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 10th. SVB Leerink cut their price objective on shares of OptimizeRx from $38.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, August 10th. Finally, Stifel Nicolaus started coverage on shares of OptimizeRx in a report on Monday, October 31st. They set a “buy” rating and a $19.00 price objective for the company.
OptimizeRx Trading Down 3.1 %
OptimizeRx stock opened at $20.87 on Monday. The firm has a 50 day moving average of $15.93 and a 200 day moving average of $20.83. The firm has a market capitalization of $357.98 million, a price-to-earnings ratio of -35.98 and a beta of 0.81. OptimizeRx has a 12-month low of $13.33 and a 12-month high of $74.69.
Institutional Inflows and Outflows
OptimizeRx Company Profile
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages.
- Get a free copy of the StockNews.com research report on OptimizeRx (OPRX)
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.